|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD 2.05 Billion
|
|
Market Size (2030)
|
USD 3.37 Billion
|
|
CAGR (2025-2030)
|
8.64%
|
|
Fastest Growing Segment
|
Phase III
|
|
Largest Market
|
West India
|
Market Overview
India Clinical Trials Market was valued at USD 2.05 Billion in 2024 and is anticipated to reach USD 3.37 Billion by 2030, with a CAGR of 8.64% during 2025-2030.
The Clinical Trials Market refers to the global industry that operates and manages clinical trials, which are crucial research
investigations. In these trials, individuals voluntarily participate to evaluate new treatments, interventions, or tests aimed at preventing, detecting, treating, or managing various diseases or medical conditions. By conducting these trials,
researchers aim to determine not only the safety and effectiveness but also the
scalability of new drugs or treatments, ensuring their potential impact on a
larger scale.
This
market encompasses a wide range of stakeholders, including pharmaceutical
companies, contract research organizations, healthcare providers, academic institutes,
and more. All these entities collaborate in a concerted effort, playing a
pivotal role in accelerating the process of drug discovery and development.
Through their collective endeavors, innovative treatments can be made available
to patients worldwide, addressing unmet medical needs and improving health
outcomes across diverse populations. This continuous pursuit of knowledge and
advancements in clinical research ultimately leads to breakthroughs that shape
the future of medicine and benefit humanity as a whole.
Key Market Drivers
Growing Demand for Clinical Trials
- India is witnessing rising demand for clinical trials as
pharmaceutical companies, medical device firms, and research organizations
increasingly rely on human evidence to validate safety, efficacy, and
therapeutic relevance before commercialization. The India clinical trials
market is benefiting from a large and diverse patient pool, which supports
broader enrolment across multiple therapeutic areas and makes the country
highly suitable for multicentre and specialty studies.
- India’s attractiveness as a clinical research destination is
also being strengthened by its hospital infrastructure, scientific talent base,
and expanding investigator networks, all of which improve operational scale and
study execution. Regulatory reforms under the New Drugs and Clinical Trials
Rules have added clarity, improved compliance confidence, and reinforced
India’s image as a credible and dependable location for global clinical
development programs.
- Registry activity highlights the scale of ecosystem
expansion and signals a more mature environment for sponsors seeking faster
patient recruitment and stronger data generation. Invest India stated that
94,730 clinical trials had been registered in the country since 2000, with
nearly 18,000 new trials registered in 2024 alone. It also noted that India
ranked as the third-largest destination for clinical trials globally in 2024,
underlining the country’s rising importance in international clinical research
outsourcing.
High R&D Expenditure of the Pharmaceutical Industry
- Rising research and development expenditure by
pharmaceutical companies is directly expanding the need for clinical trials in
India because deeper drug pipelines require structured testing across
early-stage, mid-stage, and late-stage development. As companies invest more in
specialty therapies, complex generics, and novel drug candidates, the demand
for trial sites, investigators, CRO support, and patient enrolment
infrastructure grows in parallel across the India clinical research ecosystem.
- India is well positioned to absorb this higher
R&D-driven demand because it offers a cost-efficient operating environment,
an expanding site network, and improving confidence among domestic and
multinational sponsors. Regulatory streamlining, digital oversight, and better
execution capabilities are making India more attractive for scalable
development programs, where evidence generation, protocol testing, and patient
studies are essential for regulatory approval and eventual commercialization.
- The link between higher innovation spending and stronger
trial activity is becoming increasingly visible in company disclosures. For
instance, Sun Pharma reported full-year FY25 R&D investment of "Rs
" 32,484" million" , equivalent to 6.2 percent of sales, and
said its specialty pipeline included eight novel entities in the clinical
stage. This clearly illustrates how increasing pharmaceutical R&D intensity
in India is translating into greater demand for clinical trial services and
research execution capacity.
Rising Prevalence of Diseases
- The rising prevalence of chronic and metabolic diseases is
creating a durable growth driver for clinical trials in India because a larger
patient base increases the need for new medicines, better treatment strategies,
and more population-relevant evidence. The India clinical trials market is
especially benefiting in areas such as diabetes, cardiovascular disorders, and
other long-duration conditions linked to urbanization, aging, and changing
lifestyle patterns.
- India’s scale provides a major advantage for clinical
research because high patient volumes improve recruitment feasibility and allow
studies to generate more representative data across varied demographics,
disease burdens, and geographies. This diversity is increasingly important for
sponsors that need therapies tested across heterogeneous populations and want
evidence that supports both domestic commercialization and broader regional or
global regulatory strategies.
- As disease incidence rises, investigators, hospitals, and
sponsors benefit from stronger case availability, which improves enrolment
efficiency in both common and specialty indications. For instance, the ICMR
INDIAB study cited by PIB estimated that India has 101 million people living
with diabetes and 136 million with prediabetes. This disease burden
significantly reinforces the need for sustained clinical research, therapeutic
testing, and long-term evidence generation in the country.
Increasing Research and Development Promoting Outsourcing
- Growing global R&D outsourcing is accelerating clinical
trial activity in India as pharmaceutical and biotechnology companies seek
destinations that combine scientific expertise, cost efficiency, supportive
regulation, and access to large treatment populations. India is becoming more
attractive for outsourced clinical research because sponsors can leverage a
broad network of hospitals, investigators, and specialized sites while also
benefiting from a research environment that is increasingly digitized and globally
visible.
- The country’s value proposition is particularly strong for
multicentre and specialty studies that require diverse enrolment, scalable
execution, and dependable operational delivery. This makes India relevant not
only for local clinical studies but also for global development programs where
sponsors need efficient study administration, strong patient recruitment, and
reliable data outputs aligned with international standards and timelines.
- Registry growth and multinational participation show that
outsourced demand is translating into real project flow rather than remaining a
purely theoretical advantage based on cost arbitrage. Invest India stated that
about 18,000 new clinical trials were registered in 2024 alone, while Bayer had
20 clinical trials registered in India across Phase II to Phase IV development,
supported through its Bengaluru global capability centre. This reflects
deepening outsourced research commitments by large international companies in
India.
Download Free Sample Report
Key Market
Challenges
Lack
of Skilled Workforce in Clinical Research
India’s clinical research sector faces a significant challenge due to the shortage of skilled professionals required to manage complex clinical trials and regulatory processes. Clinical research demands expertise in data analysis, medical protocols, and ethical compliance, yet current academic and training systems are not producing enough qualified talent to meet growing industry needs. This gap slows research activities and limits the efficient execution of large-scale trials.
The shortage also impacts global investment decisions, as international pharmaceutical companies prefer regions with a strong base of trained investigators, data managers, and regulatory experts. Without sufficient talent, India risks missing opportunities to expand its role as a global clinical research hub, despite its advantages in patient diversity and infrastructure.
Addressing this issue requires strengthening education and specialized training programs in clinical research. Greater collaboration between academia and industry, along with increased awareness of career opportunities, can help build a robust talent pipeline. Expanding the skilled workforce will enhance research capacity, attract global investment, and support India’s long-term growth in clinical development.
Stringent
Regulations for Patient Enrollment
Strict patient enrollment requirements remain a meaningful challenge for clinical trials in India because eligibility rules linked to age, disease status, prior treatment history, and overall medical profile are designed to protect participants and preserve scientific validity, but they also narrow the recruitable pool at the site level.
The process becomes more demanding because informed consent must be obtained only after participants are fully briefed on trial procedures, potential risks, and expected benefits, and published assessments of India’s regulatory framework note that requirements such as audio visual recording of consent in certain situations can add further operational complexity.
These safeguards are important for ethics and data integrity, yet they can lengthen screening cycles when potential volunteers hesitate over invasive procedures, time commitment, travel burden, or safety concerns, and an investigator survey in India found that complexity of study protocol was cited by 38 percent of respondents, while lack of patient awareness and sociocultural issues were each cited by 37 percent as key recruitment barriers. Delays in enrollment ultimately raise study timelines and costs for sponsors, which is one reason patient recruitment remains a decisive execution issue even in a country with strong research capabilities.
Key Market Trends
Adoption
Of New Technology in Clinical Research
The adoption of new technology is materially increasing demand for clinical trials in India because digital platforms, AI enabled workflows, and more automated regulatory processes are helping sponsors run studies with better speed, accuracy, and operational control across increasingly complex protocols.
India has become more attractive for global pharmaceutical companies and CROs as this shift combines with the country’s large and diverse patient base, and Invest India notes that 94,730 trials have been registered since 2000, with about 18,000 new clinical trials registered in 2024 alone, underlining how rapidly the research ecosystem is scaling.
The regulatory environment is also becoming more technology driven, with CDSCO requiring all clinical trial applications for cell and gene therapeutic products to move to the SUGAM online portal from July 10 2025, a step that supports faster and more standardized submissions. Digital execution is further strengthening patient centricity and decentralized trial models, since ICON says its Digital Platform supports integrated decentralized clinical trials and includes a global translation framework with more than 17 validated languages to help speed patient services and regulatory processes.
Digitalization
Of Clinical Trials
The
digitalization of clinical trials is expected to have a positive and
transformative impact on market growth. With the advancement of digital
technologies, multiple trial processes such as data capture, regulatory
compliance, logistics and supplies management, and more, have been streamlined,
leading to increased efficiency and effectiveness. This digital revolution has
revolutionized the way clinical trials are conducted, allowing for real-time
data acquisition related to safety and toxicity. The ability to rectify any
issues promptly in trial design has further facilitated market growth.
In
addition to the numerous benefits of digitalization, it is worth noting that
the cost of clinical trials in India is nearly half of that incurred in the
U.S. and Europe. This significant cost efficiency not only attracts global
pharmaceutical companies but also creates a favorable environment for
conducting clinical trials within the country. India offers a
large treatment-naïve patient pool, which is highly valuable for conducting
rigorous and diverse clinical studies. These factors, combined, contribute to
the overall growth of the market and position India as a prominent destination
for clinical research and development.
Segmental Insights
Phase Insights
Based on the phase,
the phase III segment emerged as the leader in terms of revenue share.
This can be attributed to the inherently cost-intensive nature of this phase.
Phase III trials necessitate a substantial patient population, which is one of
the primary reasons for the high cost associated with conducting these trials. The studies conducted in this phase typically span over several
years, unlike phase I and II, which contributes to the overall cost of the
trial and further bolsters the segment's dominance in the market.
On the other
hand, the phase I segment is expected to witness notable growth over the
forecast period, mainly due to the substantial research and development
(R&D) investments made by both global and local pharmaceutical and
biotechnological firms. The increasing demand for novel treatments and
biologics, driven by advancements in medical science and the growing healthcare
needs, further fuels the growth of this segment. When it comes to the different
phases of clinical trials, the market is divided into phase I, phase II, phase
III, and phase IV. Each phase plays a crucial role in the drug development
process.
Phase I primarily focuses on initial safety testing, phase II assesses
the effectiveness of the treatment, phase III evaluates the treatment's
efficacy and safety on a larger scale, and phase IV monitors the drug's
long-term effects after it has been approved and released to the market. The
continuous advancements and innovations in the field of clinical trials
contribute to the overall growth and development of the healthcare industry,
ensuring the availability of safe and effective treatments for patients
worldwide.
Study Design Insights
Based on study
design, the interventional trials segment held the largest revenue share, primarily driven by the adoption of this study design in a large number
of trials. This type of study design, which includes large randomized clinical
trials, is widely recognized as one of the most effective approaches for detecting
small to moderate effects of drugs. It offers robust means of
minimizing the influence of confounding variables, further enhancing its appeal
compared to other clinical study designs.
On the other
hand, the expanded access trials segment is expected to witness a significant
compound annual growth rate (CAGR) during the forecast period. This can be
attributed to various factors, including the rising prevalence of serious
diseases, the increasing demand for innovative treatment options, and the
substantial burden of chronic diseases in the country. These factors
collectively contribute to the growth of the expanded access trials segment,
offering greater opportunities for patients to access novel therapies and
interventions.
Download Free Sample Report
Regional Insights
The
Western region of India is emerging as a dominant force in the India Clinical
Trials Market. With its well-established and state-of-the-art infrastructure
for clinical research, including cutting-edge medical facilities and advanced
laboratories, the region offers a highly conducive and progressive environment
for conducting a wide range of clinical trials.
Maharashtra
boasts a pool of experienced professionals in the field who possess in-depth knowledge
and expertise in various therapeutic areas. These professionals are supported
by a robust network of research institutions and academic centers, fostering
collaboration and innovation in the field of clinical research. The state of Maharashtra has a high patient population, comprising diverse
demographics and a mix of urban and rural communities.
This provides ample
opportunities for recruitment and participation in clinical trials, ensuring a
comprehensive representation of the target population and enhancing the
generalizability of study results. As a result of these favorable factors and
conducive ecosystem, Maharashtra has become the preferred destination for both
domestic and international organizations looking to conduct diverse and
impactful clinical trials in the country. The state's commitment to ethical
practices, regulatory compliance, and patient safety further strengthens its
position as a leading hub for clinical research in India.
Recent Developments
In May 2025, Bharat Biotech announced that its oral cholera vaccine Hillchol had successfully completed Phase III clinical trials in India, marking a significant late-stage development milestone for an indigenous vaccine program. The company said the double-blind, randomized study enrolled 1,800 participants ranging from infants to adults across 10 clinical sites in India and evaluated safety, immunogenicity, non-inferiority, and lot-to-lot consistency against a comparator vaccine. The reported results showed strong immune responses against both Ogawa and Inaba serotypes, positioning Hillchol as a clinically important innovation with potential relevance for both domestic use and global vaccine supply.
In September 2025, Glenmark Pharmaceuticals initiated a multi-country Phase III clinical trial for Envafolimab, a subcutaneous PD-L1 inhibitor, in patients with resectable Stage III non-small cell lung cancer, with India included as a key trial geography. The company said it had received Drugs Controller General of India approval to begin patient enrollment and dosing in India, while also expanding the study footprint to other countries such as Russia, Brazil, and Mexico. This development stands out as a breakthrough clinical-trial advancement because it places India inside a pivotal global oncology program involving a novel subcutaneous immunotherapy approach.
In September 2025, Roche Pharma India announced the successful completion of the first phase of its Advanced Inclusive Research Site Alliance initiative after partnering with 10 government hospitals across the country to strengthen clinical trial readiness. The reports said the program trained nearly 400 professionals, including investigators, ethics committee members, and operational staff, to global Good Clinical Practice standards while improving digital readiness and trial-site processes. This is one of the clearest collaboration-led developments in India’s clinical trials sector because it directly expanded public-hospital capacity to participate in Phase III and IV research.
In September 2025, Mankind Pharma received CDSCO approval to begin a Phase I clinical trial for MKP11093, a novel orally administered JAK-1 inhibitor being developed for multiple autoimmune disorders. The company said the molecule was intended for conditions including rheumatoid arthritis, ulcerative colitis, plaque psoriasis, and alopecia, making the approval an important step in early-stage innovative drug development in India. This milestone is especially relevant because Phase I approvals for new molecules signal growth in India’s ability to support first-in-human and early clinical development, not just later-stage participation
Key Market Players
|
By Phase
|
By Study Design
|
By Indication
|
By Region
|
- Phase I
- Phase II
- Phase III
- Phase IV
|
- Interventional
- Observational
- Expanded Access
|
- Autoimmune
- Blood Disorders
- Pain Management
- Oncology
- CNS Condition
- Diabetes
- Obesity
- Cardiovascular
- Others
|
- North India
- East India
- West India
- South India
|
Report
Scope:
In
this report, the India Clinical Trials Market has been segmented into the following
categories, in addition to the industry trends which have also been detailed
below:
- India Clinical Trials Market, By Phase:
o
Phase I
o
Phase II
o
Phase III
o
Phase IV
- India Clinical Trials Market, By Study Design:
o
Interventional
o
Observational
o
Expanded Access
- India Clinical Trials Market, By Indication:
o
Autoimmune
o
Blood Disorders
o
Pain Management
o
Oncology
o
CNS Condition
o
Diabetes
o
Obesity
o
Cardiovascular
o
Others
- India Clinical Trials Market, By Region:
o
North
o
South
o
West
o
East
Competitive
Landscape
Company
Profiles: Detailed
analysis of the major companies present in the India Clinical Trials Market.
Available
Customizations:
India
Clinical Trials Market report with the given market data, Tech Sci
Research offers customizations according to a company's specific needs. The
following customization options are available for the report:
Company
Information
- Detailed analysis and profiling of
additional market players (up to five).
India Clinical Trials
Market is an upcoming report to be released soon. If you wish an early delivery
of this report or want to confirm the date of release, please contact us at [email protected]